| P2093 | author name string | Axel S Merseburger | |
| | Markus A Kuczyk | |
| | C A VON Klot | |
| P2860 | cites work | Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target | Q24559442 |
| | Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer | Q24685406 |
| | Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma | Q28247085 |
| | Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria | Q28265610 |
| | Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 |
| | Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 |
| | Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 | Q29615661 |
| | Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial | Q29615711 |
| | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 |
| | Pazopanib versus sunitinib in metastatic renal-cell carcinoma | Q33409916 |
| | Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group | Q33566395 |
| | Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy | Q34067987 |
| | Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. | Q34217927 |
| | Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma | Q34293726 |
| | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma | Q34495684 |
| | Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial | Q34650664 |
| | Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. | Q34658095 |
| | Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. | Q34896252 |
| | c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma | Q36551653 |
| | Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial | Q36726204 |
| | Time trends in the incidence of renal carcinoma: analysis of Connecticut Tumor Registry data, 1935-1989. | Q36732377 |
| | Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage | Q37022318 |
| | Assessing oncologic benefit in clinical trials of immunotherapy agents | Q37710860 |
| | Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors | Q37765246 |
| | Current and future systemic treatments for renal cell carcinoma | Q38019275 |
| | Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy | Q38082845 |
| | Endocrine side effects induced by immune checkpoint inhibitors. | Q38087579 |
| | SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer | Q38411931 |
| | Development and validation of a scale to measure disease-related symptoms of kidney cancer | Q39332683 |
| | Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. | Q39374983 |
| | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 |
| | Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma | Q41508355 |
| | Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience | Q44271583 |
| | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Q53021222 |
| | Interferon in renal cell carcinoma. The UCLA experience. | Q54168831 |
| P433 | issue | 6 | |
| P304 | page(s) | 903-908 | |
| P577 | publication date | 2016-04-08 | |
| P1433 | published in | Molecular and Clinical Oncology | Q27725125 |
| P1476 | title | Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma | |
| P478 | volume | 4 | |